Sanofi: Aubagio's tolerability profile is key differentiator in light of lacklustre efficacy
This article was originally published in Scrip
Executive Summary
The recent Phase III results from the TENERE study of Sanofi 's Aubagio (teriflunomide) comparing it with Rebif (interferon beta-1a; Merck Serono) in patients with relapsing forms of multiple sclerosis suggest that the once-daily oral drug's tolerability profile may prove to be its saving grace, say analysts at Datamonitor.